Navigation Links
Neogen Acquires Assets of Rivard Instruments
Date:12/4/2007

LANSING, Mich., Dec. 4 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) announced today that it has acquired the assets of Rivard Instruments, Inc., of Winnipeg, Canada. Rivard Instruments and Neogen's subsidiary, Ideal Instruments, Inc., are both manufacturers of detectable veterinary hypodermic needles.

The acquisition settles lengthy litigation between the two companies regarding numerous patents owned by each. The patent battles were centered on lawsuits filed by Ideal Instruments in federal courts in Iowa charging Rivard Instruments with patent infringement. A similar lawsuit in Canada was also settled as a part of this acquisition agreement.

Ideal Instruments and Rivard Instruments collectively own patents protecting the manufacturing and marketing of detectable veterinary hypodermic needles specially designed to reduce breakage during animal injections. The major advantage of the needles is that in the event a needle is broken with the cannula remaining in an animal muscle, it would be detected by metal detectors used in meat processing plants. The typical veterinary hypodermic needle is generally not detected. These detectable needles have been widely adopted by producers throughout the world, and several countries have mandated use of these needles, particularly in pork production. The two companies own patents or have patents pending in over 30 countries.

Details of the transaction were not disclosed.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.


'/>"/>
SOURCE Neogen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Neogen Acquires Kane Enterprises
2. Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues
3. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
4. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
5. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
6. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
7. NSF International Acquires David Begg Associates
8. United BioSource Acquires Caro Research, Leader in Simulation Modeling
9. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
10. Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services
11. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 ... Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric ... CAGR of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... security for both public and private sectors. Continue ... ...
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
Breaking Biology News(10 mins):